EGFR and non-small cell lung carcinoma: Pyrrolidine inhibits the EGFR/PI3K/Akt signaling pathway, increases P21 expression, decreases cyclin B1 expression, and inhibits EGFR-dependent NSCLC cell growth and cell cycle blockade in the G2 phase (Zhong et al., 2022).